The Clinical Desire for Pressurized Intraperitoneal Aerosol Chemotherapy in South Korea: An Electronic Survey-based Study

Eun Ji Lee, Soo Jin Park, Jeesun Lee, Jaehee Mun, Haerin Paik, Aeran Seol, Junhwan Kim, Ga Won Yim, Seung Hyuk Shim, Hee Seung Kim, Suk Joon Chang

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Aim: To evaluate the clinical desire for pressurized intraperitoneal aerosol chemotherapy (PIPAC) in South Korea. Patients and Methods: We performed an online survey on surgical oncologists between November and December 2019 using a questionnaire consisting of 20 questions. Results: A total of 164 respondents answered the questionnaire. Among those specialized in ovarian cancer, pseudomyxoma peritonei, and malignant mesothelioma 41.7-50% preferred PIPAC for the curative treatment of primary diseases, whereas 32.7-33.3% majoring in colorectal and hepatobiliary cancers chose it for the palliative treatment of recurrent diseases. Furthermore, 66.7-95.2% considered PIPAC appropriate for the cancers they specialized in, and 76-78.7% expected a treatment response of more than 50% and considered grade 1 or 2 complications acceptable. Most respondents answered the reasonable costs to purchase and implement PIPAC once at between 1,000,000-5,000,000 South Korean Won (KRW). Conclusion: Most Korean surgical oncologists expected relatively high tumor response rates with minor toxicities through the repeated implementation of PIPAC.

Original languageEnglish
Pages (from-to)363-371
Number of pages9
JournalAnticancer Research
Volume42
Issue number1
DOIs
StatePublished - Jan 2022

Keywords

  • Clinical desire
  • Cost
  • Peritoneal metastasis
  • Prerequisite
  • Pressurized intraperitoneal aerosol chemotherapy
  • Survey

Fingerprint

Dive into the research topics of 'The Clinical Desire for Pressurized Intraperitoneal Aerosol Chemotherapy in South Korea: An Electronic Survey-based Study'. Together they form a unique fingerprint.

Cite this